Cardioprotective effects of vasopeptidase inhibitors

Canadian Journal of Cardiology

Volumn 18, Issue 4, 2002, Pages 415-420

  Lapointe, Nathalie ^a   Rouleau, Jean L ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Angiotensin converting enzyme inhibitors; Bradykinin; Neutral endopeptidase inhibitors; Nitric oxide; Vasopeptidase inhibitors

Indexed keywords

ADRENOMEDULLIN; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BRADYKININ; CAPTOPRIL; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; KININ; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; OMAPATRILAT; PLASMINOGEN ACTIVATOR INHIBITOR; PROSTACYCLIN; RAMIPRIL; SODIUM ION; VASOPEPTIDASE INHIBITOR; WATER;

ANGIONEUROTIC EDEMA; BLOOD CLOTTING DISORDER; BLOOD FLOW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CELL ADHESION; CELL GROWTH; CLINICAL TRIAL; DIURESIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; ENZYME INHIBITION; EXPERIMENTAL MODEL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; HYPERTENSION; MONOCYTE; MYOCARDITIS; NONHUMAN; PEPTIDE SYNTHESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SODIUM EXCRETION; VASOCONSTRICTION; VASODILATATION; VERTIGO;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR SYSTEM; CORONARY ARTERIOSCLEROSIS; HUMANS; PYRIDINES; THIAZEPINES;

EID: 0036305486     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Endothelin antagonism in heart failure
2. Noradrenergic vascular hyper-responsiveness in human hypertension is dependent on oxygen free radical impairment of nitric oxide activity
3. Hypercontractility of vascular muscle in atherosclerosis
4. The renin-angiotensin system and sodium homeostasis
5. Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation
6. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function
7. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II
8. Atherosclerosis - An inflammatory disease
9. Bradykinin in the heart: Friend or foe?
10. The renal kallikrein-kinin system and the regulation of salt and water excretion
11. Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: Evidence for an endothelin-mediated mechanism
12. Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin
13. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines
14. Nitric oxide attenuates leukocyte endothelial interaction via P-selectin in splanchnic ischemia-reperfusion
15. Nitric oxide as anti-inflammatory agent
16. Assay of antioxidant and anti-inflammatory activity of nitric oxide in vivo
17. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
18. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: Design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study
19. Captopril in congestive heart failure: Improved left ventricular function with decreased metabolic cost
20. Drugs for heart failure that interfere with the renin-angiotensin system
21. Systemic hypertension
22. Effect of bradykinin receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
23. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis
24. Novel neurohormonal modulators in cardiovascular disorders. The therapeutic potential of endopeptidase inhibitors
25. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group
26. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial
27. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors
28. Vasodilatory action of endogenous atrial natriuretic factor in a rat model of chronic heart failure as determined by monoclonal ANF antibody
29. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts
30. Emerging treatments for hypertension: Potential role for vasopeptidase inhibition
31. Candoxatril, a neutral endopeptidase inhibitor: Efficacy and tolerability in essential hypertension
32. Chronic inhibition of endopeptidase 24.11 in essential hypertension: Evidence for enhanced attial natriuretic peptide and angiotensin II
33. Effects of UK 69 578: A novel atriopeptidase inhibitor
34. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure
35. Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension
36. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers
37. Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man
38. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo
39. Effects of inhibiting neutral endopeptidase and kininase II on coronary and systemic hemodynamics in rats
40. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): Rational design, properties, and potential cardiovascular applications of glycopril and alatriopril
41. Angiotensin I converting enzyme in human intestine and kidney. Ultrastructural immunohistochemical localization
42. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells
43. Omapatrilat
44. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure
45. Natriuretic peptides
46. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin
47. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption
48. Long-term, beneficial hemodynamic and neurohormonal effects of vasopeptidase inhibition with omapatrilat in heart failure
49. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension
50. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure
51. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats
52. Effects of omapatrilat in low, normal, and high renin experimental hypertension
53. Vasopeptidase inhibition prevents endothelial dysfunction of resistance arteries in salt-sensitive hypertension in comparison with single ACE inhibition
54. Vasopeptidase inhibition with omapatrilat prevents structural and functional changes of small arteries in salt-sensitive hypertension
55. A neutral endopeptidase inhibitor suppresses atherogenesis and improves endothelial function in hypercholesterolemic rabbits
56. Omapatrilat: Novel vasopeptidase inhibitor with anti-ischemic and anti-anginal activity in a placebo-controlled trial in stable, effort-induced angina pectoris
57. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril
58. Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs
59. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial